Vertex’s Exa-Cel: Off-Target Gene Editing Analyses Sufficient Given Robust Clinical Efficacy, FDA Panel Says

 
• By Sue Sutter
Funnel
Theoretical analyses of off-target effects may eventually lead to diminishing returns, an FDA panelist said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers